AKBA – Akebia Therapeutics Inc.
Akebia Therapeutics, Inc.AKBA
$3.65Name : Akebia Therapeutics, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $958,621,440.00
EPSttm : -0.21
Akebia Therapeutics, Inc.
$3.65
2.41%$0.09Float Short %
7.35
Margin Of Safety %
Put/Call OI Ratio
0.16
EPS Next Q Diff
-0.06
EPS Last/This Y
0.28
EPS This/Next Y
0.32
Price
3.65
Target Price
7.4
Analyst Recom
1
Performance Q
89.12
Relative Volume
1.71
Beta
0.88
Ticker: AKBA
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | AKBA | 3.26 | 0.19 | 0.04 | 42491 |
| 2025-06-03 | AKBA | 3.42 | 0.18 | 0.01 | 44618 |
| 2025-06-04 | AKBA | 3.64 | 0.17 | 0.12 | 46800 |
| 2025-06-05 | AKBA | 3.69 | 0.17 | 0.04 | 49891 |
| 2025-06-06 | AKBA | 3.96 | 0.17 | 0.00 | 50199 |
| 2025-06-09 | AKBA | 3.83 | 0.17 | 0.06 | 49690 |
| 2025-06-10 | AKBA | 3.92 | 0.17 | 0.15 | 50940 |
| 2025-06-11 | AKBA | 3.56 | 0.17 | 0.21 | 52863 |
| 2025-06-12 | AKBA | 3.68 | 0.17 | 0.04 | 53548 |
| 2025-06-13 | AKBA | 3.56 | 0.17 | 0.06 | 53383 |
| 2025-06-16 | AKBA | 3.59 | 0.17 | 0.04 | 53519 |
| 2025-06-17 | AKBA | 3.51 | 0.17 | 0.01 | 53745 |
| 2025-06-18 | AKBA | 3.57 | 0.17 | 0.01 | 54511 |
| 2025-06-20 | AKBA | 3.68 | 0.17 | 0.83 | 55178 |
| 2025-06-23 | AKBA | 3.65 | 0.16 | 0.30 | 43008 |
| 2025-06-24 | AKBA | 3.66 | 0.16 | 0.01 | 43214 |
| 2025-06-25 | AKBA | 3.68 | 0.16 | 0.19 | 44490 |
| 2025-06-26 | AKBA | 3.73 | 0.16 | 0.00 | 44606 |
| 2025-06-27 | AKBA | 3.65 | 0.16 | 0.06 | 44690 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | AKBA | 3.26 | 0.0 | - | -0.09 |
| 2025-06-03 | AKBA | 3.42 | 0.0 | - | -0.09 |
| 2025-06-04 | AKBA | 3.64 | 0.0 | - | -0.09 |
| 2025-06-05 | AKBA | 3.69 | 0.0 | - | -0.09 |
| 2025-06-06 | AKBA | 3.96 | 37.5 | - | -0.06 |
| 2025-06-09 | AKBA | 3.83 | 37.5 | - | -0.06 |
| 2025-06-10 | AKBA | 3.91 | 37.5 | - | -0.06 |
| 2025-06-11 | AKBA | 3.56 | 37.5 | - | -0.06 |
| 2025-06-12 | AKBA | 3.65 | 37.5 | - | -0.06 |
| 2025-06-13 | AKBA | 3.56 | 37.5 | - | -0.06 |
| 2025-06-16 | AKBA | 3.59 | 37.5 | - | -0.06 |
| 2025-06-17 | AKBA | 3.50 | 37.5 | - | -0.06 |
| 2025-06-18 | AKBA | 3.56 | 37.5 | - | -0.06 |
| 2025-06-20 | AKBA | 3.68 | 37.5 | - | -0.06 |
| 2025-06-23 | AKBA | 3.65 | 37.5 | - | -0.06 |
| 2025-06-24 | AKBA | 3.66 | 37.5 | - | -0.06 |
| 2025-06-25 | AKBA | 3.68 | 37.5 | - | -0.06 |
| 2025-06-26 | AKBA | 3.73 | 37.5 | - | -0.06 |
| 2025-06-27 | AKBA | 3.65 | 37.5 | - | -0.06 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | AKBA | -3.01 | 49.02 | 7.83 |
| 2025-06-03 | AKBA | -3.01 | 49.02 | 7.83 |
| 2025-06-04 | AKBA | -3.01 | 49.02 | 7.83 |
| 2025-06-05 | AKBA | -3.13 | 49.02 | 7.83 |
| 2025-06-06 | AKBA | -3.13 | 49.02 | 7.83 |
| 2025-06-09 | AKBA | -3.13 | 49.25 | 7.83 |
| 2025-06-11 | AKBA | -3.13 | 49.25 | 7.96 |
| 2025-06-12 | AKBA | -3.26 | 49.25 | 7.96 |
| 2025-06-13 | AKBA | -3.26 | 49.25 | 7.96 |
| 2025-06-16 | AKBA | -3.26 | 49.24 | 7.97 |
| 2025-06-17 | AKBA | -3.17 | 49.24 | 7.97 |
| 2025-06-18 | AKBA | -3.17 | 49.24 | 7.97 |
| 2025-06-19 | AKBA | -3.17 | 49.24 | 7.97 |
| 2025-06-20 | AKBA | -3.17 | 49.24 | 7.97 |
| 2025-06-24 | AKBA | -3.17 | 49.26 | 7.97 |
| 2025-06-25 | AKBA | -3.17 | 49.26 | 7.97 |
| 2025-06-26 | AKBA | -3.17 | 49.26 | 7.35 |
| 2025-06-27 | AKBA | -3.17 | 49.26 | 7.35 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.03
Avg. EPS Est. Current Quarter
-0.03
Avg. EPS Est. Next Quarter
-0.03
Insider Transactions
-3.17
Institutional Transactions
49.26
Beta
0.88
Average Sales Estimate Current Quarter
47
Average Sales Estimate Next Quarter
45
Fair Value
Quality Score
40
Growth Score
50
Sentiment Score
84
Actual DrawDown %
73.4
Max Drawdown 5-Year %
-98.2
Target Price
7.4
P/E
Forward P/E
49.32
PEG
P/S
5.18
P/B
38.85
P/Free Cash Flow
EPS
-0.22
Average EPS Est. Cur. Y
-0.06
EPS Next Y. (Est.)
0.26
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-24.51
Relative Volume
1.71
Return on Equity vs Sector %
-208.2
Return on Equity vs Industry %
-191.7
EPS 1 7Days Diff
EPS 1 30Days Diff
0.1
EBIT Estimation
Akebia Therapeutics, Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 181
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
stock quote shares AKBA – Akebia Therapeutics Inc. Stock Price stock today
news today AKBA – Akebia Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AKBA – Akebia Therapeutics Inc. yahoo finance google finance
stock history AKBA – Akebia Therapeutics Inc. invest stock market
stock prices AKBA premarket after hours
ticker AKBA fair value insiders trading